A sol particle homogeneous immunoassay for measuring serum cystatin C

A Trial of Pitavastatin Versus Rosuvastatin for Dyslipidemia in Chronic Kidney Disease

“…The 134 patients enrolled in this study (rosuvastatin group, n 68; pitavastatin group, n 66) were started on rosuvastatin 2.5 mg or pitavastatin 1 mg with the target LDL-C level of 100 mg/dL, and the dose level of rosuvastatin and pitavastatin could be increased up to 5 mg and 2 mg, respectively, for poor ticle-immunoassay method as described previously 8) . The eGFR (mL/min/1.73 m 2 ) was calculated as the mean eGFR value (eGFR mean) from the following equations using both CysC (eGFRcys) and S-Cr (eGFRcr): eGFRmean (eGFRcr eGFRcys)/2; eGFRcys (males) [ 9,10) .…”

Serum levels of cystatin C in elderly lung cancer patients

“…Serum levels of Cys-C in patients with lung cancer were evaluated using an automated analyzer, JCA-BM 8020 (JEOL, Tokyo, Japan) using colloidal gold particles coated with anti-Cys-C antibodies (Alfresa Pharma, Osaka, Japan) (19). Serum Cre and CRP were measured using the enzymatic method.…”

Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease

“…In addition, there was no significant change in the eGFR levels during the treatment period (from 55.1 ± 2.1 to 55.1 ± 2.1 mL/min/1.73 m 2 ). In contrast, serum cystatin C levels were significantly tin C was measured by using the fully automated solparticle-immunoassay method as described previously [12]. The hs-CRP level was measured by latex agglutination.…”

“…While the LDL-C level remains the cornerstone of decision making for the initiation of lipid-modifying therapy, it has been proposed that non-HDL-C levels should also be considered, particularly in patients with hypertriglyceridemia or CKD [12]. The rationale behind this proposal is that non-HDL-C includes the cholesterol component of all atherogenic lipoproteins, and is, therefore, a better atherogenic index than LDL-C [14].…”